1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-32.49%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
43.36%
Gross profit growth above 1.5x 5715.T's 23.20%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
347.61%
EBIT growth similar to 5715.T's 343.60%. Walter Schloss might infer both firms share similar operational efficiencies.
228.08%
Operating income growth under 50% of 5715.T's 1765.63%. Michael Burry would be concerned about deeper cost or sales issues.
140.65%
Net income growth at 75-90% of 5715.T's 167.28%. Bill Ackman would press for improvements to catch or surpass competitor performance.
140.64%
EPS growth at 75-90% of 5715.T's 167.27%. Bill Ackman would push for improved profitability or share repurchases to catch up.
140.64%
Diluted EPS growth at 75-90% of 5715.T's 167.27%. Bill Ackman would expect further improvements in net income or share count reduction.
-0.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-265.94%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-265.94%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-90.11%
Negative 10Y revenue/share CAGR while 5715.T stands at 24.06%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-90.11%
Negative 5Y CAGR while 5715.T stands at 24.06%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-90.11%
Negative 3Y CAGR while 5715.T stands at 24.06%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
94.46%
Positive long-term OCF/share growth while 5715.T is negative. John Neff would see a structural advantage in sustained cash generation.
94.46%
Positive OCF/share growth while 5715.T is negative. John Neff might see a comparative advantage in operational cash viability.
94.46%
Positive 3Y OCF/share CAGR while 5715.T is negative. John Neff might see a big short-term edge in operational efficiency.
101.47%
Similar net income/share CAGR to 5715.T's 111.67%. Walter Schloss would see parallel tailwinds or expansions for both firms.
101.47%
5Y net income/share CAGR similar to 5715.T's 111.67%. Walter Schloss might see both on parallel mid-term trajectories.
101.47%
3Y net income/share CAGR similar to 5715.T's 111.67%. Walter Schloss would attribute it to shared growth factors or demand patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.89%
Inventory growth well above 5715.T's 13.29%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.96%
Positive asset growth while 5715.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
1.29%
50-75% of 5715.T's 1.94%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
8.68%
Debt growth far above 5715.T's 1.88%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.